{"id":447778,"date":"2010-03-19T13:21:22","date_gmt":"2010-03-19T17:21:22","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=69356"},"modified":"2010-03-19T13:21:22","modified_gmt":"2010-03-19T17:21:22","slug":"theraclone-raises-1-5m","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/447778","title":{"rendered":"Theraclone Raises $1.5M"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/VC\/\">VC<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Theraclone Sciences, the Seattle-based developer of antibody drugs, has raised another $1.5 million in equity financing, according to a regulatory <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1310967\/000131096710000004\/xslFormDX01\/primary_doc.xml\">filing<\/a>. The new equity comes after Theraclone received $29 million in venture capital in March 2007 from Arch Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Equities. The company also has funding for its HIV research and development from the International AIDS Vaccine Initiative and <a href=\"http:\/\/www.xconomy.com\/seattle\/2009\/10\/05\/seattles-theraclone-strikes-18m-deal-to-make-flu-fighting-antibodies-with-japanese-company\/\">Japan-based Zenyaku Kogyo<\/a>.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/03\/19\/theraclone-raises-1-5m\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Theraclone%20Raises%20$1.5M%20http:\/\/xconomy.com\/?p=69356\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/03\/19\/theraclone-raises-1-5m\/&#038;t=Theraclone%20Raises%20$1.5M\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/03\/19\/theraclone-raises-1-5m\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Theraclone+Raises+%241.5M&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F03%2F19%2Ftheraclone-raises-1-5m%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=41f6f0df8d48ca651f5e95c5478c0c72&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=41f6f0df8d48ca651f5e95c5478c0c72&#038;p=1\"\/><\/a><br \/>\n<!-- foo --><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/xNjMShJjrzgmdbVfxg-UvOWsd8k\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/xNjMShJjrzgmdbVfxg-UvOWsd8k\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/xNjMShJjrzgmdbVfxg-UvOWsd8k\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/xNjMShJjrzgmdbVfxg-UvOWsd8k\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/ETAF1tawVPg\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, VC, deals Luke Timmerman wrote: Theraclone Sciences, the Seattle-based developer of antibody drugs, has raised another $1.5 million in equity financing, according to a regulatory filing. The new equity comes after Theraclone received $29 million in venture capital in March 2007 from Arch Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-447778","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/447778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=447778"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/447778\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=447778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=447778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=447778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}